PhotoCure - Results second quarter 2004
Oslo, Norway, 20 August 2004 Metvix approved in the US PhotoCure ASA (Oslo Stock Exchange: PHO) publishes today its results for the second quarter 2004. Highlights from the report include: · Metvix® approved in the US for the treatment of actinic keratosis. · Metvix launches initiated in Australia, Belgium and Switzerland. · The number of Metvix units sold to pharmacies in the Nordic region increased by 66% compared to the corresponding quarter in 2003. · Hexvix® - A pharmacokinetic study required for approval in Sweden for this product was successfully completed in June